Advertisement

A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents

      Highlights

      • The beneficial roles of statin and ACEI/ARB in STEMI patients are well-known.
      • It is not known which is the better therapy between statin with ACEI or statin with ARB combination.
      • Statin with ACEI is better than statin with ARB in reducing mortality rate.
      • MACE, MI, and revascularization rates are similar between these two groups.

      Abstract

      Background and aims

      Studies of the comparative clinical outcomes between statin with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in ST-segment elevation myocardial infarction (STEMI) patients are limited. We compared 2-year clinical outcomes between statin with ACEI or ARB therapy in STEMI patients after successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES).

      Methods

      A total of 11,706 STEMI patients were enrolled and separated into two groups: the ACEI group (statin + ACEI, n = 8705) and the ARB group (statin + ARB, n = 3001). The primary endpoint was major adverse cardiac events (MACE) defined as all-cause death, recurrent MI (re-MI), and any coronary revascularization. Secondary endpoints were the individual components of MACE and target vessel failure (TVF).

      Results

      After propensity score-matched (PSM) analysis, two PSM groups (2729 pairs, n = 5458, C-statistic = 0.675) were generated. The cumulative incidences of MACE, re-MI, and any coronary revascularization were similar between the two groups. However, the cumulative incidences of all-cause death (hazard ratio [HR], 1.548; 95% confidence interval [CI], 1.091–2.197; p = 0.014) and cardiac death (HR, 1.850; 95% CI, 1.218–2.811; p = 0.004) were significantly higher in the ARB group compared with the ACEI group after PSM analysis.

      Conclusions

      The combination of statin with ACEI may be the preferred treatment strategy to reduce mortality rates in STEMI patients after successful PCI with DES rather than statin with ARB in this study during a 2-year follow-up period.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kostapanos M.S.
        • Milionis H.J.
        • Elisaf M.S.
        An overview of the extra-lipid effects of rosuvastatin.
        J. Cardiovasc. Pharmacol. Ther. 2008; 13: 157-174
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • et al.
        Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Ibanez B.
        • James S.
        • Agewall S.
        • et al.
        • ESC Scientific Document Group
        2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
        Eur. Heart J. 2018; 39: 119-177
        • Probstfield J.L.
        • O'Brien K.D.
        Progression of cardiovascular damage: the role of renin-angiotensin system blockade.
        Am. J. Cardiol. 2010; 105: 10A-20A
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • et al.
        2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology foundation/American heart association task force on practice guidelines.
        J. Am. Coll. Cardiol. 2013; 61: e78-e140
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • et al.
        American College of Cardiology foundation/American heart association task force on practice guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology foundation/American heart association task force on practice guidelines.
        Circulation. 2013; 127: e362-425
        • Kim Y.H.
        • Her A.Y.
        • Jeong M.H.
        • et al.
        Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: comparison between STEMI and NSTEMI.
        Atherosclerosis. 2019; 280: 166-173
        • Mancia G.
        • Fagard R.
        • Narkiewicz K.
        • et al.
        2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension [ESH] and of the european society of Cardiology (ESC).
        Eur. Heart J. 2013; 34: 2159-2219
        • James P.A.
        • Oparil S.
        • Carter B.L.
        • et al.
        2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        J. Am. Med. Assoc. 2014; 311: 507-520
        • Kim Y.H.
        • Her A.Y.
        • Jeong M.H.
        • et al.
        Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
        Heart Vessel. 2019; 34: 237-250
        • Teramoto T.
        • Sasaki J.
        • Ishibashi S.
        • Birou S.
        • Daida H.
        • Dohi S.
        • Japan Atherosclerosis Society
        • et al.
        Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version.
        J. Atheroscler. Thromb. 2013; 20: 517-523
        • Hillegass W.B.
        • Alam G.K.
        High-dose atorvastatin was superior to standard-dose pravastatin for reducing death or major cardiovascular events in acute coronary syndromes.
        ACP J. Club. 2004; 141: 33
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • et al.
        Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        J. Am. Med. Assoc. 2001; 285: 1711-1718
        • Stenestrand U.
        • Wallentin L.
        Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival.
        J. Am. Med. Assoc. 2001; 285: 430-436
        • Miyauchi K.
        • Kimura T.
        • Morimoto T.
        • et al.
        Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (Japan-ACS): rationale and design.
        Circ. J. 2006; 70: 1624-1628
        • Kim Y.H.
        • Her A.Y.
        • Jeong M.H.
        • et al.
        Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: data from the Korea Acute Myocardial Infarction Registry.
        Cathet. Cardiovasc. Interv. 2018; (Nov 25)https://doi.org/10.1002/ccd.27985
        • Dickstein K.
        • Kjekshus J.
        • OPTIMAAL Steering Committee of the OPTIMAAL Study Group
        Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
        Lancet. 2002; 360: 752-760
        • McMurray J.
        • Solomon S.
        • Pieper K.
        • et al.
        The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
        J. Am. Coll. Cardiol. 2006; 47: 726-733
        • Ma T.K.
        • Kam K.K.
        • Yan B.P.
        • et al.
        Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.
        Br. J. Pharmacol. 2010; 160: 1273-1292
        • Zhang X.
        • Xie Y.W.
        • Nasjletti A.
        • et al.
        ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption.
        Circulation. 1997; 95: 176-182
        • Ferrari R.
        • Rosano G.M.
        Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context.
        Int. J. Cardiol. 2013; 166: 286-288
        • Laufs U.
        • La Fata V.
        • Plutzky J.
        • et al.
        Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
        Circulation. 1998; 97: 1129-1135
        • Laufs U.
        • Fata V.L.
        • Liao J.K.
        Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.
        J. Biol. Chem. 1997; 272: 31725-31729
        • Hoang V.
        • Alam M.
        • Addison D.
        • et al.
        Efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in coronary artery disease without heart failure in the modern statin era: a meta-analysis of randomized-controlled trials.
        Cardiovasc. Drugs Ther. 2016; 30: 189-198
        • Perondi R.
        • Saino A.
        • Tio R.A.
        • et al.
        ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.
        Circulation. 1992; 85: 2004-2013
        • Strauss M.H.
        • Hall A.S.
        Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox.
        Circulation. 2006; 114: 838-854
        • da Silva A.R.
        • Fraga-Silva R.A.
        • Stergiopulos N.
        • et al.
        Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.
        Eur. J. Clin. Investig. 2015; 45: 274-287
        • Naghavi M.
        • Libby P.
        • Falk E.
        • et al.
        From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
        Circulation. 2003; 108: 1664-1672
        • Magnoni M.
        • Ammirati E.
        • Moroni F.
        Impact of cardiovascular risk factors and pharmacologic treatments on carotid intraplaque neovascularization detected by contrast-enhanced ultrasound.
        J. Am. Soc. Echocardiogr. 2019; 32: 113-120
        • Weber K.T.
        • Brilla C.G.
        Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system.
        Circulation. 1991; 83: 1849-1865
        • Ramchand J.
        • Patel S.K.
        • Srivastava P.M.
        • et al.
        Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease.
        PLoS One. 2018; 13e0198144
        • Ortiz-Pérez J.T.
        • Riera M.
        • Bosch X.
        • et al.
        Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study.
        PLoS One. 2013; 8e61695
        • Dézsi C.A.
        Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
        Am. J. Cardiovasc. Drugs. 2014; 2014: 167-173
        • Kim Y.H.
        • Her A.Y.
        • Jeong M.H.
        • et al.
        Comparison between beta-blockers with angiotensin-converting enzyme inhibitors and beta-blockers with angiotensin II type I receptor blockers in ST-segment elevation myocardial infarction after successful percutaneous coronary intervention with drug-eluting stents.
        Cardiovasc. Drugs Ther. 2019; 33: 55-67
        • Athyros V.G.
        • Tziomalos K.
        • Florentin M.
        • et al.
        Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
        Curr. Med. Res. Opin. 2010; 26: 839-842
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • et al.
        Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy.
        N. Engl. J. Med. 2005; 352: 20-28
        • Fonarow G.C.
        • Wright R.S.
        • Spencer F.A.
        • et al.
        National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality.
        Am. J. Cardiol. 2005; 96: 611-616
        • Athyros V.G.
        • Kakafika A.I.
        • Tziomalos K.
        • et al.
        Pleiotropic effects of statins--clinical evidence.
        Curr. Pharmaceut. Des. 2009; 15: 479-489
        • Wiggins B.S.
        • Saseen J.J.
        • Page 2nd, R.L.
        • et al.
        American heart association clinical pharmacology committee of the council on clinical Cardiology; council on hypertension; council on quality of care and outcomes research; and council on functional genomics and translational biology. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association.
        Circulation. 2016; 134: e468-e495
        • Stone G.W.
        • Lansky A.J.
        • Pocock S.J.
        • et al.
        HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
        N. Engl. J. Med. 2009; 360: 1946-1959